1 Robust metabolomic age prediction based on a wide selection of metabolites

- 2 Key words: metabolomics, ridge regression, prediction, aging, xenobiotics
- 3 Tarig Faguih¹, Astrid van Hylckama Vlieg¹, Praveen Surendran^{2,3,4,5,6}, Adam S. Butterworth^{2,3,4,7,8},
- 4 Ruifang Li-Gao^{1,9}, Renée de Mutsert¹, Frits R. Rosendaal¹, Raymond Noordam¹⁰, Diana van Heemst¹⁰,
- 5 Ko Willems van Dijk^{11,12,13}, Dennis O. Mook-Kanamori^{1,14}
- ¹ Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands;
 <u>T.O.Faquih@lumc.nl</u> (T.O.F.); (A.v.H.V.); (R.L.-G.); (R.d.M); (F.R.R.);
 (D.O.M.-K.)
- ² British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary
 Care, University of Cambridge, Cambridge, UK; (P.S.)
- ³ British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge, UK;
 (P.S.)
- ⁴ Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge,
 Cambridge, UK; (P.S.)
- ⁵ Rutherford Fund Fellow, Department of Public Health and Primary Care, University of Cambridge,
 Cambridge, UK; (P.S.)
- 17 ⁶ GSK plc., Stevenage, England, United Kingdom
- ⁷ Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, UK.
- ⁸ NIHR Blood and Transplant Research Unit in Donor Health and Behaviour, Department of Public
 Health and Primary Care, University of Cambridge, Cambridge, UK.
- ⁹ Metabolon, Inc., Morrisville, North Carolina, United State of America; (R.L.-G.)
- ¹⁰ Department of Internal Medicine, Section of Gerontology and Geriatrics, Leiden University Medical
 Center, Leiden, The Netherlands; (R.N.); (D.v.H.)
- ¹¹ Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands;
 (K.W.v.D)
- ¹² Department of Internal Medicine, Division of Endocrinology, Leiden University Medical Center,
 Leiden, The Netherlands; (K.W.v.D)
- ¹³ Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center,
 Leiden, The Netherlands; (K.W.v.D)
- ¹⁴ Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, The
- 31 Netherlands; (D.O.M.-K.)

32 Abstract

Chronological age is a major risk factor for numerous diseases. However, chronological age does not 33 34 capture the complex biological aging process. Biological aging can occur at a different pace in 35 individuals of the same chronological age. Therefore, the difference between the chronological age 36 and biologically driven aging could be more informative in reflecting health status. Metabolite levels 37 are thought to reflect the integrated effects of both genetic and environmental factors on the rate of aging, and may thus provide a stronger signature for biological age than those previously developed 38 39 using methylation and proteomics. Here, we set out to develop a metabolomic age prediction model 40 by applying ridge regression and bootstrapping with 826 metabolites (of which 678 endogenous and 41 148 xenobiotics) measured by an untargeted high-performance liquid chromatography mass spectrometry platform (Metabolon) in 11,977 individuals (50.2% men) from the INTERVAL study 42 43 (Cambridge, UK). Participants of the INTERVAL study are relatively healthy blood donors aged 18-75 44 years. After internal validation using bootstrapping, the models demonstrated high performance with 45 an adjusted R² of 0.82 using the endogenous metabolites only and an adjusted R² of 0.83 when using 46 the full set of 826 metabolites with age as outcome. The latter model performance could be indicative 47 of xenobiotics predicting frailty. In summary, we developed robust models for predicting metabolomic 48 age in a large relatively healthy population with a wide age range.

49 Introduction

50 Chronological age is a major risk factor for a multitude of diseases (1, 2). The biology of aging 51 comprises complex and multifactorial processes that are influenced by genetic, lifestyle and 52 environmental factors (3-5). Evidently, the rate of biological aging varies between individuals, as in contrast to other individuals of the same age group, wherein, some individuals are able to live to an 53 54 older chronological age without age-related diseases and disability (3). This suggests that 55 chronological age does not align with the biological aging process. For this reason, several studies have 56 aimed to capture the signature of biological changes due to aging process by predicting its rate based 57 on biological factors using, for example, DNA methylation (6) and proteins (7).

58 Metabolomic profiling aims to identify small molecules that are mostly substrates or products of 59 metabolism (metabolites). The number of metabolomics studies has increased in recent years due to 60 major technological advances and the availability of (validated and high throughput) commercial and 61 noncommercial analyses platforms. In addition, the current platforms have improved their capability 62 to detect and quantify large numbers of endogenous and xenobiotic metabolites(8, 9). Since individual 63 metabolomic profiles reflect the influences of both genetic and acquired factors, they are thought to 64 provide a more holistic representation of biological processes, such as aging (8, 9). Furthermore, as

65 metabolomic profiles are strongly affected by chronological age (4, 10) and sex (11, 12), they have 66 been used to develop prediction models of chronological age (i.e., the metabolomic age) (13-16). 67 However, predicting metabolomic age using metabolomics had limited success or faced 68 methodological limitations due to several reasons. First, some studies used a relatively small sample 69 size to predict age using hundreds or even thousands of metabolite predictors (10, 17). The inclusion 70 of a larger number of predictors than the number of samples may cause overfitting and bias. Second, 71 previous metabolomic age studies used targeted platforms, such as the Nightingale platform, that 72 specifically measure a small number of lipoproteins and some low-molecular metabolites. This limits 73 the variety of the metabolites and the information used for the prediction of age. Third, studies may 74 be limited by the age distribution of the cohort study. This may restrict the model to a specific age 75 range which affects the generalizability of the model in other studies and other age groups (10). 76 Fourth, generalizability may also be reduced if the model is developed in cohorts with an oversampling 77 of individuals with specific disease outcomes or specific population characteristics (7, 13). Fifth, 78 statistical methodology such as stepwise selection, have been reported to cause overfitting of the 79 prediction model (18). Finally, it is challenging to examine the model's validity and generalizability in 80 external studies or different populations particularly due to the dynamic nature of metabolite levels 81 (19-21).

82 In this study, we aimed to develop a model to predict metabolomic age in a large healthy population 83 with a widespread age range, using a single untargeted metabolomics platform. To attain this goal, 84 we developed a prediction model using data from the INTERVAL study (22) (University of Cambridge, 85 Cambridge, UK). Metabolomic profiles were available in 11,977 participants as measured using Metabolon's (Durham, North Carolina, USA) untargeted metabolomics platform. These 86 87 measurements included a broad range of endogenous and xenobiotic metabolites (n=1,363) from various biochemical pathways, thereby enabling the capture of metabolites related to a vast range of 88 89 ageing effects.

90 Methods

91 INTERVAL Study

The INTERVAL study is a prospective cohort study of approximately 50,000 participants nested within a pragmatic randomized sample of blood donors (22). Between 2012 and 2014, blood donors, aged la years and older, were consented and recruited from 25 National Health Service Blood and Transplant (NHSBT) static donor centers across the UK. The INTERVAL study was approved by The National Research Ethics Service (11/EE/0538). Individuals with major disease (myocardial infarction,

97 stroke, cancer etc.) as well as those who reported being unwell or having had recent illness or infection 98 or did not fulfill the other criteria required for blood donation (22, 23) were ineligible for the study. 99 Therefore, participants included in the study were predominantly healthy. Participants completed 100 online questionnaires addressing basic lifestyle and health-related information, including self-101 reported height and weight, ethnicity, smoking status, alcohol consumption, doctor-diagnosed 102 anemia, use of medications (hormone replacement therapy, iron supplements) and menopausal 103 status (22). Untargeted metabolomic data were available in 11,979 individuals (age range 18 - 75). 104 Two individuals had incorrect or missing height/weight values and were therefore excluded from the 105 study. Thus, the final sample size for the current study was 11,977.

106 Untargeted metabolomic measurements

107 Untargeted metabolomic measurements were quantified at Metabolon Inc. (Durham, North Carolina, 108 USA) using Metabolon™ Discovery HD4 platform. In brief, this process involves four independent ultra-109 high-performance liquid chromatography mass spectrometry (UHPLC-MS/MS) platforms (24, 25). Of these platforms, two used positive ionization reverse phase chromatography, one used negative 110 ionization reverse phase chromatography, and one used hydrophilic interaction liquid 111 112 chromatography negative ionization (25). Known metabolites were annotated at Metabolon Inc. with 113 chemical names, super pathways, sub pathways, biochemical properties, and compound identifiers 114 from various metabolite databases. Metabolomic measurements in the INTERVAL study were 115 conducted in three batches (n=4087, 4566, and 3326). Subsequent harmonization and quality checks were performed between the batches by Metabolon. All metabolite measurements were scaled to a 116 117 median of 1.

118 Selection of Predictors

119 We aimed to select metabolites consistently and reliably measured by the Metabolon platform. In 120 total 1,411 metabolites were measured in the INTERVAL study. First, we removed metabolites 121 completely missing in at least one of the batches (n=175). Second, we excluded metabolites without 122 annotation (unnamed metabolites) (n=258), keeping only endogenous and xenobiotic metabolites. 123 These metabolites were excluded as they are inconsistently measured by the platform and are highly variable between batches and studies. Moreover, the lack of full annotation increases the uncertainty 124 125 that we are using the same metabolite across batches and studies and leaves no secondary 126 information for further verification. Third, we excluded metabolites measured in less than 100 127 individuals (n=30). Fourth, to ensure that the metabolites that are used for our model are not unique 128 for the INTERVAL study, we cross-referenced our dataset with an independent study with Metabolon

measurements. For this we used the Netherlands Epidemiology of Obesity (NEO) study, a populationbased (n=599) cohort study of individuals aged 45–65 years (26, 27). Based on this comparison, we additionally excluded 122 metabolites that were not detected in the NEO study. The final set of metabolites included 826 metabolites, with 678 endogenous and 148 xenobiotic metabolites that

133 were confirmed to be regularly measured by the Metabolon platform (Figure 1).

134 Missing value imputation

Missing values were imputed using the pipeline as described in our previous work (27). In brief, endogenous metabolites were imputed by multiple imputation using chained equations method to generate five imputed datasets (m=5). For each metabolite with missing values, we used the outcome variable (i.e., age), 5-10 highly correlated related metabolites, body mass index (BMI), center number where the blood samples were collected, and the batch number to impute the missing values. Xenobiotic metabolites were imputed to zero to account for true missingness.

141 Model Development

142 For the development of the model, we used ridge regression (28) to reduce potential overfitting. Cross 143 validation was performed (n=10) in each imputed dataset to calculate the optimal shrinkage term 144 (lambda). Subsequently the mean of the lambda values was used to develop the model on the stacked 145 imputed datasets (i.e., all 5 datasets combined as one). Accordingly, the weight of the observations in the stacked dataset was set to 1/m = 1/5 = 0.2 (20). As the outcome (age) is a continuous variable, we 146 assessed the fit of the model by deriving the R². As an additional sensitivity test, we used generalized 147 148 additive model (GAM) to examine and calculate the R² for the nonlinear correlation. Internal validation 149 was performed using bootstrapping (b=100). Bootstrapping results were used for the optimization of 150 R^2 and the calculation of the mean squared error (MSE) and the mean absolute error (MAE) of the 151 model. Two models were developed using two sets of the selected metabolite predictors. First, we used the full set of endogenous and xenobiotic metabolites (n=826) to develop "model A". Second, 152 we used only the endogenous metabolites (n=678) to develop "model B". As previous studies found 153 154 that metabolomic profiles (12, 29) and aging (30-32) are influenced by the sex of individuals, we included sex as an additional predictor in both models. 155

156 Sample size considerations

The primary database used to create the prediction model was the INTERVAL study (n= 11,977) with 826 predictors. We used the formulas described by Riley et al. (33) to confirm that our sample size (n) and number of predictor (p) are sufficient to minimize overfitting and provide high prediction precision. First, we calculated Copas global shrinkage factor for our data (34, 35) to see if it is above 161 the recommended 0.9 threshold (33). Based on this calculation the estimated shrinkage factor was 0.95 if the adjusted R² of the model was assumed to be 0.7. Second, we calculated the sample size 162 required to ensure a small difference between the R² and the adjusted R² for the development model. 163 164 Assuming the adjusted R^2 was 0.7 again and a small desired R^2 difference (R^2_{diff} =0.025), then the sample size required to achieve this should be at least n=9913. Third, we checked the sample size 165 166 required for precise residual standard deviation of the model. Accordingly, we found the multiplicative 167 margin of error (MMOE) to be less than 10% (MMOE =1.3%) using our n and p in the INTERVAL study. 168 Finally, we checked the precision of the mean predicted outcome value (predicted age) of the model. 169 We used n and p for the INTERVAL study and assumed that predicted age would have a mean of 45 170 and a variance of 35. Accordingly, the upper and lower bounds were approximately 45.34 and 44.65 respectively. Thus, the MMOE for the mean predicted outcome was less 1% (MMOE= 45.34 /45 = 171 172 1.007 = 0.7%). Therefore, the sample size of the INTERVAL study was optimal to minimize overfitting, optimism, and provide a precise estimation of the residual standard deviation and mean predicted 173

174 values.

175 **Results**

176 **Population characteristics**

177 Characteristics of the total INTERVAL study population and age subgroups are summarized in Table 1. 178 In total 11,977 individuals were included and had a normal age distribution with a mean age of 45 years and a range of 18 – 75 years. The number of men and women was approximately equal (50.2% 179 180 were men). BMI was largely in the recommended range of 18.5-24.9 kg/m² (36) with a mean BMI of 22.8 kg/m² and was similar in all age groups. 181

182


	Total	18 to 25	25 to 35	35 to 45	45 to 55	55 to 65	65 to 75
Ν	11977	1178	2245	2152	2867	2602	811
Age (years), mean (range)	45 (18-75)						
Men, n (%)	6019 (50.2%)	485 (41.2%)	965 (42.3%)	1042 (48.4%)	1560 (54.4%)	1480 (56.9%)	546 (67.3%)
BMI (kg/m ²), mean (SD)	22.8 (4.2)	21.3 (4.0)	22.0 (4.2)	23.3 (4.4)	23.5 (4.3)	23.0 (3.9)	22.6 (3.5)
183	Table 1. Characteristics of the INTERVAL study population.						

Table 1. Characteristics of the INTERVAL study population.

184 **Metabolomic Age Prediction**

185 Prediction models A (endogenous plus xenobiotic metabolites) and B (endogenous metabolites only) 186 were developed in the INTERVAL study using ridge regression. The workflow including metabolite 187 selection, missing value imputation, and analyses are summarized in Figure 1. Internal validation using 188 bootstrapping (resampling n = 100) and optimization provided an R² of 0.83 (MSE=31, MAE=4.4) for model A, and 0.82 (MSE=33.7, MAE=4.6) for model B. The R² for the generalized additional model 189 (GAM) were slightly higher for both models, 0.85 for model A and 0.84 for model B (Figure 2, 190 191 Supplementary Table 1, Supplementary Figure 1). Full tables with the intercept, sex and metabolite 192 coefficients for model A and B are provided in Supplementary Table 2. This table also contains the 193 mean values for the metabolites from the INTERVAL study.

194





195

196 Figure 1: Flowchart of the selection of predictor metabolites and the development steps for the

197

metabolomic age prediction model in the INTERVAL study





202 Discussion

203 In this study, we developed a prediction model for metabolomic age based on metabolite 204 measurements, including a wide range of endogenous and xenobiotic metabolites belonging to a 205 variety of biochemical pathways. The metabolomic measurements were performed in a single study 206 using the same metabolomic platform and harmonized for within study and between batch variation. 207 Importantly, we used multiple imputation, ridge regression, and bootstrapping (20) to develop and 208 internally validate the metabolomic age prediction models. We developed two models, with the first 209 model A using both endogenous and xenobiotic metabolites (n=826), and the second model B using the endogenous metabolites only (n=678). Both models had high adjusted R^2 (model A = 0.83; Model 210 211 B = 0.82), however, model B had slightly higher MSE and MAE, indicating higher error for the predicted values. 212

213 Ridge Regression for Metabolomic Age

Our metabolomic age model is based on ridge regression which generates shrinkage factors that shrink metabolite coefficients with weak influence on the model to small values. Unlike methods such as LASSO and elastic net regression, this shrinkage never causes the coefficients to reach zero. Therefore, unlike those methods, ridge regression does not perform selection of predictors, in this case metabolites, due to the shrinkage term. Thus, the model consistently includes the same metabolites during the cross validation and internal validation by bootstrapping (20). Ridge regression

thus ensures rigorousness and consideration of all the selected metabolite predictors. In addition, we found in our model that nonlinear GAM R² to be slightly higher than linear R² in both models. Figure 2 also shows that the GAM line curves at the edges of the age ranges. Therefore, predicting metabolomic age from this model in a nonlinear form, by adding a quadratic term or using a spline function, may further expand the model flexibility.

225 Strengths and Limitations

226 A major strength of our current study is the development of robust metabolomic age prediction 227 models based on a large number of metabolites measured in a large cohort with a wide age 228 distribution. This sample size was confirmed to fit the required criteria for developing a model with 229 low overfitting (33). Furthermore, the INTERVAL study included relatively healthy blood donors as 230 participants. Blood donors are prescreened for a number of common diseases, making it a suitable 231 study to develop a metabolomic age without being affected by specific disease-related effects on 232 metabolites. Unlike previous metabolomic age predictors (alternatively referred to as metabolomic "clocks"), we developed our model using the latest Metabolon metabolomics platform that measures 233 a large selection of metabolites. An advantage of this platform is the inclusion of xenobiotics, such as 234 235 those derived from medication or pollution as well as endogenous metabolites. Thus, we were able to 236 include metabolites originating from various internal and external sources. The xenobiotic metabolites 237 represent some of the acquired environmental and lifestyle exposures of individuals that could play a role in biological aging. For example, medication metabolites could be a predictor of frailty. However, 238 our study has two limitations. First, because the INTERVAL study does not have data for health-related 239 240 outcomes, we could not assess the effects of different disease outcomes and health phenotypes on 241 the metabolomic age. Second, as the INTERVAL study used here was cross sectional, we could not 242 examine the model overtime or examine the ability of metabolomic age to predict disease outcomes 243 or mortality in a future time point.

244 External Validation for Metabolomic Age and Future Applications

Prediction models may suffer from overfitting due to selection bias, small sample size, methodology limitations, and lack of internal validation and calibration during development. However, another common issue regarding prediction modelling, such as the case with metabolomic age, is the challenge to externally validate them. This a common issue with prediction models in general. Indeed, few studies perform external validation of prediction models (19, 37). The reasons for the lack of external validation include the difficulty of applying and reproducing the prediction model method, lack of the full prediction variables to develop the model in the new dataset, or a lack of an appropriate sample 252 size for external validation. Without external validation, the quality of the models cannot be properly 253 assessed, and a model could still be overfitted despite presenting good results during internal 254 validation(20, 21, 38). We took advantage of the sample size and wide age range to use a stringent 255 ridge regression and internal validation method to develop the metabolomic age model. The resulting model demonstrated a high R² for the metabolomic age. The high R² from our models is unlikely to be 256 257 due be overfitting as we considered and calculated the power and sensitivity of the model based on the sample size and number predictors (33), in addition to the rigorous prediction modelling 258 259 methodology. The metabolomic age was able to predict chronological age well but not perfectly. The 260 missing 0.2 from R^2 is likely a reflection the biological aging process captured by the metabolomic age. 261 However, future robust external validation, using weak and moderate calibrations in other 262 populations (38) would be valuable for the metabolomic age models presented in this paper.

263 Several age prediction models have been developed that utilize different biological measurements 264 such as targeted metabolomics (7, 14), proteomics (7), and epigenetics (DNA methylation)(6). These 265 studies have reported that the metabolites were a strong predictor of body mass index, metabolic 266 syndrome, cancer (7), type 2 diabetes, and cardiovascular disease (14). Furthermore, other biological 267 clocks using proteomics and epigenetics were reported to be associated with depression and other 268 outcomes (7). Therefore, it will be valuable to apply the prediction models presented in this paper in 269 large longitudinal cohorts and examine the metabolomic age in relation to calendar age with the 270 aforementioned phenotypes and other health related outcomes. Assessing the association between 271 the residual between the chronological and metabolomic age with disease and health phenotypes overtime will provide clinically relevant prediction. The prediction strength will indicate the 272 273 robustness of our model and provide the means to for external validation and re-calibration of the 274 model.

275 In addition to our aim of addressing primary issues of the development of metabolomic age models, 276 the Metabolon platform is expanded on the range of metabolites that can potentially be a better 277 predictor of age. For example, previous metabolomic age studies have not measured or included 278 xenobiotic metabolites. In our study, we were able to include this additional group of metabolites in 279 model A. Furthermore, Model A may also be used in tandem with metabolomic age from targeted platforms, and biological clocks of different biological molecules measurements, similar to the work 280 by Jansen et al. (7), to possibly improve or compare their predictive performance and their ability of 281 capturing the effects of health-related phenotypes. 282

283 Conclusions

We developed metabolomic age prediction models in a large relatively healthy population using a wide array of endogenous and xenobiotic metabolites. In model A with the endogenous and xenobiotic metabolites and in model B with endogenous metabolites only, the R² of the linear fit was 0.82 and 0.83, respectively. We provided the full list of metabolites and their coefficients for both models. This data can enable other researchers to replicate our metabolomic age prediction model, externally validate it in their own studies with different disease outcomes and combine them with other age prediction models.

291 References

- 292 North BJ, Sinclair DA. The intersection between aging and cardiovascular disease. Circ Res. 1. 293 2012;110(8):1097-108. doi:10.1161/CIRCRESAHA.111.246876 294 Broglio SP, Eckner JT, Paulson HL, Kutcher JS. Cognitive decline and aging: the role of 2. 295 concussive and subconcussive impacts. 2012;40(3):138. 296 Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 3. 297 2013;153(6):1194-217. doi:10.1016/j.cell.2013.05.039 298 4. Hoffman JM, Lyu Y, Pletcher SD, Promislow DEL. Proteomics and metabolomics in ageing 299 research: from biomarkers to systems biology. Essays Biochem. 2017;61(3):379-88. 300 doi:10.1042/EBC20160083 301 5. Brooks-Wilson AR. Genetics of healthy aging and longevity. 2013;132(12):1323-38. 302 Horvath S. DNA methylation age of human tissues and cell types. Genome Biology. 6. 303 2013;14(10):3156. doi:10.1186/gb-2013-14-10-r115 304 7. Jansen R, Han LK, Verhoeven JE, et al. An integrative study of five biological clocks in somatic 305 and mental health. Elife. 2021;10. doi:10.7554/eLife.59479 306 8. Alonso A, Marsal S, Julia A. Analytical methods in untargeted metabolomics: state of the art 307 in 2015. Front Bioeng Biotechnol. 2015;3:23. doi:10.3389/fbioe.2015.00023 308 Rattray NJW, Deziel NC, Wallach JD, et al. Beyond genomics: understanding exposotypes 9. through metabolomics. Hum Genomics. 2018;12(1):4. doi:10.1186/s40246-018-0134-x 309 310 Rutledge J, Oh H, Wyss-Coray T. Measuring biological age using omics data. Nature Reviews 10. 311 Genetics. 2022. doi:10.1038/s41576-022-00511-7 312 Martin FJ, Montoliu I, Kussmann M. Metabonomics of ageing - Towards understanding 11. 313 metabolism of a long and healthy life. Mech Ageing Dev. 2017;165(Pt B):171-9. 314 doi:10.1016/j.mad.2016.12.009 315 Yu Z, Zhai G, Singmann P, et al. Human serum metabolic profiles are age dependent. Aging 12. 316 Cell. 2012;11(6):960-7. doi:10.1111/j.1474-9726.2012.00865.x 317 13. Macdonald-Dunlop E, Taba N, Klarić L, et al. A catalogue of omics biological ageing clocks 318 reveals substantial commonality and associations with disease risk. Aging. 2022;14(2):623-59. 319 doi:10.18632/aging.203847 320 van den Akker EB, Trompet S, Barkey Wolf JJH, et al. Metabolic Age Based on the BBMRI-NL 14. 321 (1)H-NMR Metabolomics Repository as Biomarker of Age-related Disease. Circulation. Genomic and 322 precision medicine. 2020;13(5):541-7. doi:10.1161/circgen.119.002610 323 15. Hertel J, Friedrich N, Wittfeld K, et al. Measuring Biological Age via Metabonomics: The 324 Metabolic Age Score. J Proteome Res. 2016;15(2):400-10. doi:10.1021/acs.jproteome.5b00561 325 Rist MJ, Roth A, Frommherz L, et al. Metabolite patterns predicting sex and age in 16. 326 participants of the Karlsruhe Metabolomics and Nutrition (KarMeN) study. PLoS One. 327 2017;12(8):e0183228. doi:10.1371/journal.pone.0183228 328 Hwangbo N, Zhang X, Raftery D, et al. A Metabolomic Aging Clock Using Human 17. 329 Cerebrospinal Fluid. The Journals of Gerontology: Series A. 2021;77(4):744-54. 330 doi:10.1093/gerona/glab212 %J The Journals of Gerontology: Series A 331 18. Smith G. Step away from stepwise. Journal of Big Data. 2018;5(1):32. doi:10.1186/s40537-332 018-0143-6 333 19. Ramspek CL, Jager KJ, Dekker FW, Zoccali C, van Diepen M. External validation of prognostic 334 models: what, why, how, when and where? Clinical Kidney Journal. 2020;14(1):49-58. 335 doi:10.1093/ckj/sfaa188 %J Clinical Kidney Journal 336 20. Steyerberg EW. Clinical Prediction Models. 2nd ed. Cham, Switzerland: Springer 337 International Publishing; 2019. 338 21. Bleeker SE, Moll HA, Steyerberg EW, et al. External validation is necessary in prediction 339 research:: A clinical example. Journal of Clinical Epidemiology. 2003;56(9):826-32.
- 340 doi:https://doi.org/10.1016/S0895-4356(03)00207-5

Moore C, Sambrook J, Walker M, et al. The INTERVAL trial to determine whether intervals

between blood donations can be safely and acceptably decreased to optimise blood supply: study

343 protocol for a randomised controlled trial. Trials. 2014;15:363-. doi:10.1186/1745-6215-15-363 344 23. NHS Blood Donation Who can give blood. 2022. https://www.blood.co.uk/who-can-give-345 blood. 346 24. Evans A, Bridgewater B, Liu Q, et al. High resolution mass spectrometry improves data quantity and quality as compared to unit mass resolution mass spectrometry in high-throughput 347 348 profiling metabolomics. 2014;4(2):1. Rhee EP, Waikar SS, Rebholz CM, et al. Variability of Two Metabolomic Platforms in CKD. 349 25. Clinical Journal of the American Society of Nephrology. 2019;14(1):40. doi:10.2215/CJN.07070618 350 351 26. de Mutsert R, den Heijer M, Rabelink TJ, et al. The Netherlands Epidemiology of Obesity 352 (NEO) study: study design and data collection. Eur J Epidemiol. 2013;28(6):513-23. 353 doi:10.1007/s10654-013-9801-3 354 Faquih T, van Smeden M, Luo J, et al. A Workflow for Missing Values Imputation of 27. 355 Untargeted Metabolomics Data. Metabolites. 2020;10(12). doi:10.3390/metabo10120486 356 28. Hoerl AE, Kennard RW. Ridge Regression: Biased Estimation for Nonorthogonal Problems. 357 Technometrics. 1970;12(1):55-67. doi:10.1080/00401706.1970.10488634 358 29. Saner C, Harcourt BE, Pandey A, et al. Sex and puberty-related differences in metabolomic 359 profiles associated with adiposity measures in youth with obesity. Metabolomics. 2019;15(5):75. 360 doi:10.1007/s11306-019-1537-y 361 30. Hägg S, Jylhävä J. Sex differences in biological aging with a focus on human studies. eLife. 362 2021;10:e63425. doi:10.7554/eLife.63425 363 31. Nakamura E, Miyao KJTJoGSABS, Sciences M. Sex differences in human biological aging. 364 2008;63(9):936-44. 365 McCrory C, Fiorito G, McLoughlin S, et al. Epigenetic clocks and allostatic load reveal 32. 366 potential sex-specific drivers of biological aging. 2020;75(3):495-503. 367 Riley RD, Snell KIE, Ensor J, et al. Minimum sample size for developing a multivariable 33. 368 prediction model: Part I - Continuous outcomes. Statistics in medicine. 2019;38(7):1262-75. 369 doi:10.1002/sim.7993 370 34. Copas JB. Regression, prediction and shrinkage. Journal of the Royal Statistical Society: Series 371 B. 1983;45(3):311-35. Copas JB. Using regression models for prediction: shrinkage and regression to the mean. 372 35. 373 Statistical methods in medical research. 1997;6(2):167-83. doi:10.1177/096228029700600206 36. 374 WHO WHO. A healthy lifestyle - WHO recommendations. World Health Organization: WHO. 375 2010. 376 37. Siontis GCM, Tzoulaki I, Castaldi PJ, Ioannidis JPA. External validation of new risk prediction 377 models is infrequent and reveals worse prognostic discrimination. Journal of Clinical Epidemiology. 378 2015;68(1):25-34. doi:https://doi.org/10.1016/j.jclinepi.2014.09.007 379 38. Van Calster B, McLernon DJ, van Smeden M, et al. Calibration: the Achilles heel of predictive 380 analytics. BMC Medicine. 2019;17(1):230. doi:10.1186/s12916-019-1466-7 381

382

341

342

22.

383 Funding

The INTERVAL study was funded by NHSBT and the NIHR Blood and Transplant Research Unit in 384 385 Donor Health and Genomics (NIHR BTRU-2014-10024). The trial's coordinating centre at the Department of Public Health and Primary Care at the University of Cambridge, Cambridge, UK, has 386 387 received core support from the UK Medical Research Council (G0800270), British Heart Foundation (SP/09/002), and the NIHR Cambridge Biomedical Research Centre. Investigators at the University of 388 389 Oxford, Oxford, UK, have been supported by the Research and Development Programme of NHSBT, 390 the NHSBT Howard Ostin Trust Fund, and the NIHR Oxford Biomedical Research Centre through the 391 programme grant NIHR-RP-PG-0310-1004. We thank the blood donors who participated in the trial

- and NHSBT's operational staff.
- 393 The NEO study is supported by the participating Departments, the Division, and the Board of
- 394 Directors of the Leiden University Medical Centre, and by the Leiden University, Research Profile
- 395 Area 'Vascular and Regenerative Medicine'. The analyses of metabolites are funded by the VENI
- 396 grant (ZonMW-VENI Grant 916.14.023) of D.O.M.-K., D.v.H. and R.N. were supported by a grant of
- the VELUX Stiftung [grant number 1156]. T.O.F. was supported by the King Abdullah Scholarship
- Program and King Faisal Specialist Hospital & Research Center [No. 1012879283].

399 Conflicts of Interest

- 400 P.S. is an associate director of applied and statistical genetics at GlaxoSmithKline plc. A.S.B. reports
- 401 institutional grants from AstraZeneca, Bayer, Biogen, BioMarin, Bioverativ, Novartis, Regeneron and
- 402 Sanofi. R.L.-G. is a part-time clinical research consultant for Metabolon, Inc. All other co- authors
- 403 have no conflicts of interest to declare.
- 404 Acknowledgments and Disclosures
- 405 The authors of the NEO study thank all participants, all participating general practitioners for inviting
- 406 eligible participants, all research nurses for data collection, and the NEO study group: Pat van
- 407 Beelen, Petra Noordijk, and Ingeborg de Jonge for coordination, laboratory, and data management.
- 408 The NEO study was approved by the medical ethical committee of the Leiden University Medical
- 409 Centre (LUMC) and all participants provided written informed consent.
- 410 Author Contributions
- 411 T.O.F.- conceptualization, data curation, formal analysis, investigation, methodology, software,
- 412 visualization, writing-original draft. P.S. supervision, conceptualization, project administration,
- resources, funding acquisition, writing review & editing. A.S.B project administration, resources,
- funding acquisition, writing review & editing. R.L.-G.- validation, writing review & editing. R.d.M.-
- 415 project administration, resources, funding acquisition, writing review & editing. R.N. and D.V.H.-
- 416 funding acquisition, writing review & editing. F.R.R.- funding acquisition. A.v.H.V. and K.W.v.D-
- 417 conceptualization, supervision, writing review & editing. D.O.M.-K.- conceptualization, supervision,
- 418 funding acquisition, writing review & editing.